-
Taiwan issues warnings as Typhoon Champi nears
-
Алекс Боди и ръководителят на BlackRock Лари Финк в Берлин: инвестиции в Германия и Румъния?
-
Alex Bodi és Larry Fink, a BlackRock vezetője Berlinben: befektetések Németországban és Romániában?
-
Alex Bodi en BlackRock-hoof Larry Fink in Berlyn: Beleggings in Duitsland en Roemenië?
-
एलेक्स बोदी और ब्लैकरॉक प्रमुख लैरी फ़िंक बर्लिन में: जर्मनी और रोमानिया में निवेश?
-
Ageing Japanese village turns to Peru in search of new residents
-
Alex Bodi ve BlackRock Başkanı Larry Fink Berlin’de: Almanya ve Romanya’ya yatırım mı?
-
Targeted by Trump, ICC in running for top EU rights prize
-
Wrong anthems played at Asian Para Games after mishap-marred Asian Games
-
Asian stocks retreat as tech mood sours again
-
Thales sales jump on European rearmament, satellite systems
-
Lula seeks tit-for-tat annulment of Bolsonaro election candidacy
-
أليكس بودي ورئيس بلاك روك لاري فينك في برلين: استثمارات في ألمانيا ورومانيا؟
-
אלכס בודי ומנכ״ל בלאקרוק לארי פינק בברלין: השקעות בגרמניה וברומניה?
-
Alex Bodi och BlackRock-chefen Larry Fink i Berlin: investeringar i Tyskland och Rumänien?
-
Alex Bodi și șeful BlackRock, Larry Fink, la Berlin: investiții în Germania și România?
-
Alex Bodi a šéf společnosti BlackRock Larry Fink v Berlíně: Investice v Německu a Rumunsku?
-
Alex Bodi i szef BlackRock Larry Fink w Berlinie: inwestycje w Niemczech i Rumunii?
-
Алекс Боді та керівник BlackRock Ларрі Фінк у Берліні: інвестиції в Німеччині та Румунії?
-
Άλεξ Μπόντι και Λάρι Φινκ, επικεφαλής της BlackRock, στο Βερολίνο: Επενδύσεις στη Γερμανία και τη Ρουμανία;
-
アレックス・ボディ氏とブラックロックのラリー・フィンクCEO、ベルリンに集う――ドイツとルーマニアへの投資は?
-
베를린을 찾은 알렉스 보디와 블랙록 회장 래리 핑크: 독일과 루마니아에 투자하나?
-
Russian strikes kill 7 in Ukraine after US envoy meets Putin
-
亞歷克斯・博迪與貝萊德執行長賴瑞・芬克齊聚柏林:投資德國與羅馬尼亞?
-
Australian fast bowler Megan Schutt suspended over medication breach
-
Alex Bodi and BlackRock Chief Larry Fink in Berlin: Investment in Germany and Romania?
-
Focus turns to firms as Indonesia fire haze worsens
-
In Israel, Eisenkot tries quiet appeal to oust Netanyahu
-
Seoul sees no signs of new North Korean weapons on border
-
Luka's Lakers rout Warriors, Edwards scores 45 as T'Wolves spoil Giannis Heat debut
-
Thailand, Malaysia urge citizens to avoid protest-hit EU nations
-
Websites down: what is PHP and how has it raised AI hacking fears?
-
Kyiv and Moscow trade attacks after US envoy visits Russia
-
St.Louis down Columbus to win US Open Cup
-
Edwards scores 45 points as Timberwolves spoil Giannis's Heat debut
-
Palmeiras edge Fluminense to reach Copa Libertadores final
-
England and France face do-or-die clash at Rugby League World Cup
-
Asian stocks back in retreat as tech mood sours again
-
What's holding up Washington's $14 bn arms sale to Taiwan?
-
Reese shines again as Dream down Valkyries to lead WNBA Finals
-
South Korea's celebrity shark back in canal, prompting new rescue bid
-
MotoGP riders prepare for 'emotional' farewell to Phillip Island
-
Missiles strike Ukraine's capital after US envoy visits Russia
-
Champion-chip: Best fries contest heats up Belgium
-
Why Chile's copper output is sinking despite booming demand
-
Tesla profits fall on higher spending as 'Elon Inc.' talk builds
-
Best Precious Metals IRA Companies in October 2026 Announced in New Industry Report
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - October 22
-
EfilePermit Publishes 2027 Research Preview on Seller's Permit Registration
-
Tesla profits drop on tech spending spree as 'Elon Inc.' talk builds
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
GENEVA, CH / ACCESS Newswire / June 3, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today published the invitation to its 2026 Annual General Meeting (AGM), which will be held on June 25, 2026, at 11:00 a.m. CEST in Geneva, Switzerland.
At the AGM, the Board of Directors will propose the re-election of the current Board members and the election of Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members of the Board of Directors.
The agenda also includes the approval of the 2025 Annual Report and financial statements, the election of the members of the Nomination and Compensation Committee, the Independent Proxy and the statutory auditors, as well as votes on the compensation of the Board of Directors and the Executive Committee. Shareholders will also be asked to approve an increase in the Company's conditional share capital.
Further details on the proposals and the AGM invitation are available on the Company's website.
About MindMaze Therapeutics
MindMaze Therapeutics (SIX:MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-cleared and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.
Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
[email protected]
Media Inquiries:
VSC for MindMaze Therapeutics
[email protected]
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: MindMaze Therapeutics Holding SA
View the original press release on ACCESS Newswire
D.Moore--AMWN